Alkermes plc. 8-K

What Happened Alkermes plc announced on July 6, 2026 that it and Amneal Pharmaceuticals LLC have terminated the Authorized Generic Product Supply Agreement that was originally signed on September 9, 2025. Under that agreement, Alkermes Pharma Ireland Limited (APIL), a wholly owned indirect subsidiary of Alkermes, had agreed to supply a limited quantity of an authorized generic version of VIVITROL® (naltrexone for extended-release injectable suspension) to Amneal for a one-year period following a Third Party ANDA product launch, in exchange for a premium above APIL’s fully burdened manufacturing cost and a share of Net Profits.

Key Details

• Agreement date: entered September 9, 2025; termination effective July 6, 2026.
• Product: authorized generic version of VIVITROL® (the “Amneal AG Product”).
• Commercial terms: supply at a premium to APIL’s fully burdened manufacturing cost plus a share of any Net Profits.
• Post-termination: no penalties were incurred, no further payments or obligations are owed by APIL or Amneal, and both parties mutually released all claims related to the agreement.
• Triggering events: Alkermes notified Amneal it had not met certain Agreement terms and provided a cure period; before that period expired Amneal informed Alkermes it would not order any batches.

Why It Matters For investors, this is a contract termination rather than a dispute or financial penalty—Alkermes reports no penalties and no remaining obligations under the agreement. The termination removes a previously expected source of incremental revenue (authorized generic VIVITROL sales and potential profit share) tied to the Amneal AG Product, but the filing does not quantify any material financial impact. The company’s disclosure suggests no ongoing legal exposure between the parties stemming from this contract.